文献速递淋巴瘤造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

霍奇金淋巴瘤自体移植后克隆性造血与治疗相关髓系肿瘤

Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2024-04-18

该回顾性队列纳入321例接受自体外周血干细胞移植的霍奇金淋巴瘤患者,中位移植年龄34岁,对干细胞产品进行靶向DNA测序。结果显示14.3%的患者干细胞产品存在克隆性造血,为治疗相关髓系肿瘤的独立预测因素(aHR 4.50)。TP53和/或PPM1D突变与治疗相关髓系肿瘤风险(HR 7.29)及非复发死亡风险(HR 4.17)升高相关。

要点

  • 干细胞产品中克隆性造血见于14.3%的霍奇金淋巴瘤自体移植患者,为治疗相关髓系肿瘤独立预测因素(aHR 4.50)。
  • TP53和/或PPM1D突变者治疗相关髓系肿瘤风险升高7.29倍,非复发死亡风险升高4.17倍。
  • 克隆性造血与复发相关死亡无关联,TP53突变者均发生治疗相关髓系肿瘤。

核心结论

  • 干细胞产品中存在TP53和/或PPM1D突变增加霍奇金淋巴瘤患者自体移植后治疗相关髓系肿瘤和非复发死亡风险,可能支持替代治疗策略。

研究设计与样本

  • 回顾性队列研究,纳入321例接受自体外周血干细胞移植的霍奇金淋巴瘤患者,中位移植年龄34岁(范围18-71岁)。
  • 对干细胞产品进行靶向DNA测序,检测克隆性造血相关或髓系恶性肿瘤相关基因的致病突变。

主要发现

  • 46例(14.3%)患者干细胞产品检出克隆性造血,最常见突变为DNMT3A(n=25)、PPM1D(n=7)、TET2(n=7)和TP53(n=5)。
  • 干细胞产品存在克隆性造血是治疗相关髓系肿瘤的独立预测因素(aHR 4.50,95%CI 1.54-13.19)。
  • TP53和/或PPM1D突变者治疗相关髓系肿瘤风险为无克隆性造血突变者的7.29倍(95%CI 1.72-30.94)。
  • TP53和/或PPM1D突变者非复发死亡风险为无克隆性造血突变者的4.17倍(95%CI 1.25-13.87)。
  • 克隆性造血与复发相关死亡无关联;所有TP53突变者均发生治疗相关髓系肿瘤,而单纯DNMT3A突变(无TP53或PPM1D共突变)者均未发生。

临床怎么用

  • 原文结论指出,TP53和/或PPM1D突变的存在可能支持替代治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS: We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71). Targeted DNA sequencing of PBSC products performed for CH-associated or myeloid malignancy-associated genes identified pathogenic mutations in these patients. RESULTS: CH was identified in the PBSC product of 46 patients (14.3%) with most prominent representation of DNMT3A (n = 25), PPM1D (n = 7), TET2 (n = 7), and TP53 (n = 5) mutations. Presence of CH in the PBSC product was an independent predictor of t-MN (adjusted hazard ratio [aHR], 4.50 [95% CI, 1.54 to 13.19]). Notably all patients with TP53 mutations in the PBSC product developed t-MN, whereas none of the patients with DNMT3A mutations alone (without co-occurring TP53 or PPM1D mutations) did. Presence of TP53 and/or PPM1D mutations was associated with a 7.29-fold higher hazard of t-MN when compared with individuals carrying no CH mutations (95% CI, 1.72 to 30.94). The presence of TP53 and/or PPM1D mutations was also associated with a 4.17-fold higher hazard of nonrelapse mortality (95% CI, 1.25 to 13.87). There was no association between CH and relapse-related mortality. CONCLUSION: The presence of TP53 and/or PPM1D mutations in the PBSC product increases the risk of post-aPBSCT t-MN and nonrelapse mortality among patients with HL and may support alternative therapeutic strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yan C, Richard MA, Gibson CJ, et al. Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma. J Clin Oncol. 2024. PMID: 38635938. doi:10.1200/JCO.23.02547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。